GlassScriptPhysician profile
Yemane B Bahta
NPI 1316020316
$3,584.86
in general payments reported to CMS, 2019-2025
13 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $222 · 2021: $750 · 2022: $435 · 2023: $428 · 2024: $983 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,640.38 | 2019-2024 | Dovato, Cabenuva |
| Abbvie INC. | $606.84 | 2021-2024 | Dalvance |
| Merck Sharp & Dohme LLC | $303.12 | 2019-2025 | Prevymis, Zerbaxa |
| Shionogi INC | $291.76 | 2024-2025 | Fetroja |
| Allergan, INC. | $252.62 | 2019-2020 | |
| Dexcom, INC. | $143.98 | 2023 | Dexcom G7 Gss (161) |
| Insmed, INC. | $140.23 | 2020-2025 | Arikayce |
| Gilead Sciences, INC. | $78.92 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $49.26 | 2024 | Xacduro |
| Paratek Pharmaceuticals, INC. | $24.02 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $22.98 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.70 | 2019 | |
| Mylan Institutional INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yemane Bahta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.